| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_318f4696fe772797d47ff9d8bfc529d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1ef528967b68251335075bb52bb3a936
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_384df48970bf728d823ffcbf1747ad09 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 |
| filingDate |
2012-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_575941d724850af049b8e8338fb669a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88008c1e7bcd4f8146093f283628c84d |
| publicationDate |
2012-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012151559-A2 |
| titleOfInvention |
Cytotoxic therapy by proton flux modulation |
| abstract |
Compositions and methods for treating cancer are described. Some of the methods include administering to a cancer patient in need thereof a substance, such as a carbonic anhydrase inhibitor, that at a therapeutic dose produces a metabolic acidosis in humans; and administering to the patient at least one of: (a) a monocarboxylate transport inhibitor; (b) a sodium-hydrogen exchange inhibitor; (c) a chloride-bicarbonate exchange inhibitor; or (d) a proton pump inhibitor; wherein the at least one of (a) through (d) is in an amount effective to induce selective cytotoxicity in cancer cells relative to noncancerous cells in humans. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023139462-A1 |
| priorityDate |
2011-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |